Model Medicines, Inc.
Model Medicines engineers first-in-class small molecules against biological choke points, using AI to advance pipeline-in-a-pill therapeutics across high-impact diseases.
Funding history
About Model Medicines, Inc.
How much funding has Model Medicines, Inc. raised?
Model Medicines, Inc. has raised $15.7M in total funding. The most recent round was Series A.
Where is Model Medicines, Inc. headquartered?
Model Medicines, Inc. is headquartered in La Jolla, CA.
What does Model Medicines, Inc. do?
Model Medicines engineers first-in-class small molecules against biological choke points, using AI to advance pipeline-in-a-pill therapeutics across high-impact diseases.
What problem does Model Medicines, Inc. solve?
Many diseases (including the 'triple threat' of RSV, flu, and COVID-19, plus various cancers and other conditions) lack effective, broad-acting small-molecule drugs that hit their core underlying biological drivers.
What's Model Medicines, Inc.'s solution?
Model Medicines uses an AI-driven end-to-end engine to design, discover, and develop first-in-class small molecules that target shared biological 'choke points' (such as RdRp Thumb-1 and BRD4) underlying multiple diseases.
What makes Model Medicines, Inc. different?
Its lead candidate MDL-001 is described by outside researchers as an orally available, direct-acting, broad-spectrum antiviral showing multi-log viral load reductions across multiple viral families, an effect the page says no prior oral antiviral has demonstrated.
What makes Model Medicines, Inc. notable?
Model Medicines, an AI-first drug discovery platform, was founded by Daniel Haders II, PhD, who presented the company at the 2026 BIO Investment & Growth Summit.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.